With $8.8 billion raised by global biotechnology companies through May 10 this year, there seems to be no shortage of money available. About $2.9 billion of that funding has gone to private companies, $2.2 billion to public offerings and a hefty $3.7 billion to other public company financing vehicles. (BioWorld Today)